BioMark Metabolic Panel – Biomark Diagnostics

BioMark Liquid Biopsy Metabolic Panel

Validating a new high-powered metabolic panel assay for early diagnosis of Lung Cancer.

Metabolic Panel Assays

BioMark Liquid Biopsy Metabolic Panel Assays

BioMark has invested and successfully discovered and validated a new high-powered metabolic panel assay for early diagnosis of Lung Cancer. This performance panel assay has clinically demonstrated superior detection capabilities for early stage I / II Lung Cancers using urine and plasma. This is a major breakthrough in Lung Cancer diagnostics and strategically positions the company in a vintage position for high risk lung cancer screening market which currently uses low dose CT scans (LDCT). ML being incorporated in the analysis of the assay.

Cancer Research

Panels Being Developed for Other Cancers

Glioblastoma (GBM)
Breast Cancer
Head & Neck Cancer

Application:

Screening for high risk group
Precision medicine
Assess high risk relapse population cohort
Assess malignancy

Clinical Trials:

Spermidine/spermine N-acetyltransferase 1 (SSAT 1) Gene Expression in Human Cancer

Principal Investigator: Dr. Andrew Maksymiuk, MD, Cancer Care Manitoba

Status: Open

Spermidine/spermine N-acetyltransferase 1 (SSAT1) Gene Expression and Identification of High-Performance Metabolites in Human Cancer (Amended)

Principal Investigator: Dr. Andrew Maksymiuk, MD, Cancer Care Manitoba
Co-Investigator: Dr. Daniel S. Sitar, Ph.D, University of Manitoba
Co-Investigator: Dr. Paramjit Tappia, Ph.D, Asper Clinical Research Institute

Status: Open

Glioblastoma (GBM)

CancerCare Manitoba ethics approval obtained for the protocol
Patients to be recruited newly diagnosed and treated
Utilize both SSAT1 and new panels
Expand clinical trial sites in N. America

Breast Cancer

Identified and validated several putative markers
Expanding trial samples
Incorporate other clinical and imaging data

Head / Neck Cancer

In discussion with a major European centre to develop a comprehensive Omics panel of markers for high relapse cancer cohort
Modify protocol and potentially extend trial to additional North American sites after Health Canada and ethics approvals are granted.

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

Investor Inquires

1 604 370 0779
130 3851 Shell Road
Richmond BC
Canada V6X 2W2

Rashid A. Bux (CEO)
info@biomarkdiagnostics.com